HealthLinx to Launch Cancer Diagnostic in Singapore
The HealthLinx OvPlex ovarian cancer diagnostic will be released in Singapore in July. Inex has the rights to distribute the diagnostic in Singapore, Thailand, Vietnam, Malaysia, Indonesia and India.
The latter plans to use Singapore as the platform to launch into other South East Asian countries including Thailand, Vietnam, Malaysia, Indonesia and ultimately India. Collectively, these jurisdictions equate to an opportunity of over 1.5 million tests and the royalty per test that will be received by HealthLinx will approximately S$30 (US$21.80).
The test will be available in Singapore clinics and through private GPs from July at a cost of approximately S$200 (US$145.71).
The company is also finalizing preparations for the second larger study that will screen 1150 samples using the existing OvPlex panel and an additional two novel biomarkers: AGR2 and HTX010.
The study will be a robust comparison of sensitivity and specificity for the detection of ovarian cancer, particularly for early stage diagnosis in symptomatic women. The company’s expectation is to increase the performance of the diagnostic from the current 94 percent to greater than 97 percent.
